#### Open Access Full Text Article

## ORIGINAL RESEARCH

# Real-World Study on Patient Satisfaction and Tolerability After Switching to Preservative-Free Latanoprost

This article was published in the following Dove Press journal: *Clinical Ophthalmology* 

### Carl Erb<sup>1</sup> Ingeborg Stalmans<sup>2</sup> Milko Iliev<sup>3</sup> Francisco José Muñoz-Negrete D<sup>4</sup>

 <sup>1</sup>Eye Clinic Wittenbergplatz, Berlin, Germany; <sup>2</sup>Department of Ophthalmology, University Hospitals Leuven, Leuven, Belgium;
 <sup>3</sup>Ophthalmology Department, University of Bern, Inselspital, Bern, Switzerland;
 <sup>4</sup>Servicio de Oftalmología, Hospital Universitario Ramón y Cajal, Universidad de Alcalá, IRYCIS, Madrid, España

Servicio de Oftalmología, Hospital Universitario Ramón y Cajal, Universidad de Alcalá, IRYCIS, Madrid, España Tel +34 913 36 80 00 Email franciscojmunoz@telefonica.net



**Purpose:** Patient satisfaction is important in the treatment of glaucoma. Suboptimal compliance and impaired long-term outcome are a likely result of poor tolerability. The present multicentre, international, transverse, epidemiological survey was conducted to assess the satisfaction of patients who had received preservative-free latanoprost (PFL) for at least 3 months.

**Patients and Methods:** A total of 1872 patients from 6 European countries, treated with PFL for at least 3 months, were included in this survey. Prior to PFL treatment, patients were to be treatment naïve or currently treated for their glaucoma. During a single routine consultation, patients completed a questionnaire concerning global satisfaction and satisfaction based on tolerability.

**Results:** In total, 76.2% had been previously treated; 69.4% had received preserved and 6.8% preservative-free (PF) topical treatment. After 3 months of PFL treatment, a large majority of patients (95.3%) were satisfied or very satisfied with their PFL treatment and were, overall, significantly (p<0.0001) more satisfied with PFL than with their previous treatment; 4.2% were either unsatisfied or very unsatisfied. Overall, 97.3% of originally treatment-naïve patients were satisfied (50.1%) or very satisfied (47.2%) with their PFL. Ocular surface disease was diagnosed in 9.2% of patients (n=173) and was mainly mild (76.9%). Patient satisfaction with PFL was very high.

**Conclusion:** PFL may be considered a valuable first-choice treatment in glaucoma patients. **Keywords:** glaucoma, prostaglandin, preservative-free latanoprost, patient satisfaction, tolerability, tear substitutes, intra-ocular pressure, ocular surface disease, conjunctival hyperaemia

### Introduction

Glaucoma is a chronic disorder that requires long-term treatment. In common with other insidious diseases such as hypertension or type-2 diabetes, obtaining patient compliance and long-term adherence with treatment is a key factor in achieving a good clinical outcome.

Whilst efficacy is a rewarding goal for both the patient and physician, many factors can impact the patient's compliance and treatment regime. Among these factors, which include convenience, comfort and ease of use, the tolerability of the medication is a main issue.<sup>1</sup> According to the European Glaucoma Society "A patient who complains about side effects is usually not adherent to therapy".<sup>2</sup> The basic problem with glaucoma patients is that in most cases they do not perceive

Clinical Ophthalmology 2021:15 931-938

© 0201 Erb et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution — Non Commercial (unported, v3.0). License (http://creativecommons.org/licenses/by-nc/3.0). By accessing the work you hereby accept the Terms. Non-commercial use of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

Correspondence: Francisco José Muñoz-Negrete

visual disturbances and, therefore, do not feel impaired in their daily life. However, glaucoma therapy leads to farreaching changes on the ocular surface, which not only leads to inflammatory changes on the cellular level, but also subjectively cause discomfort for the patients, limiting their quality of life.<sup>3–7</sup> Ocular surface toxicity is frequently associated with not only the active ingredient in the eye drops, but also with the preservative contained in the formulation, which prevents bacterial growth.<sup>8</sup>

Topically applied latanoprost has become the first line treatment for glaucoma and ocular hypertension.<sup>9</sup> Not only is it effective and well tolerated, but patients adhere to their treatment significantly more easily with latanoprost than with bimatoprost, travoprost or timolol.<sup>10–13</sup> The advent of a patented topical latanoprost formulation without preservative offered a higher tolerability of prostaglandin glaucoma medication, with relatively fewer symptoms of ocular surface disease that could compromise adherence to treatment.<sup>14–19</sup>

Given the importance of long-term adherence to treatment in glaucoma and the impact of tolerability upon it, surprisingly little attention has been paid to the patient's experience of topical preservative-free (PF) glaucoma medications. The present study was conceived to determine the degree of satisfaction among treatment-naïve patients or those who had recently switched to PF latanoprost in single-use dose units (PFL, Monoprost<sup>®</sup>, Laboratoires Théa, France)

### **Methods**

The study was conducted between 2013 and 2015, according to the principles of Good Epidemiological Practices.<sup>20</sup> Approvals were obtained from local or National Ethics Committees in Berlin (Charité's Ethics committee, Berlin, Germany), Bern (Inselspital Bern, Switzerland), Leuven (Université catholique Leuven, Belgium) and from the National Data Protection Committee of Spain (CNPD) Madrid, Spain,) according to the regulations at the investigational sites. According to local regulations, no ethics committee approvals were obtained for the Netherlands and Portugal. All patients provided written informed consent before participating in the study.

Eligible adult subjects had to have a documented diagnosis of glaucoma or ocular hypertension and had been treated with PFL for at least 3 months at the time of the study visit or could have been treatment-naive.

The study was a multicentre, transverse, epidemiological survey, conducted during a single consultation with a routine clinical examination. It was performed in 337 private ophthalmological practices. Ophthalmologists were chosen from national databases on the basis of feasibility as well as geographical and national balance.

Ophthalmologists were asked to consecutively recruit 10 patients (5 in Switzerland) who had received PFL for glaucoma or ocular hypertension for at least 3 months at the time of the study visit.

Gender, age, ophthalmological and other medical history, date of glaucoma diagnosis or ocular hypertension, type and stage of glaucoma based on visual field damage were recorded, along with the patient's intraocular pressure (IOP). The investigator also recorded the history of the patients' previous glaucoma therapy (if applicable) and the reason for switching to PF latanoprost. Intraocular pressure, presence of ocular surface disease (OSD) and Tear-film Break-Up-Time (TBUT, classified into three groups (>10sec, 5 to 10 sec and <5 sec) were assessed.

For patients who used tear substitutes, the investigator documented whether such use had increased, decreased or remained unchanged after the switch to PFL and whether the patient was using eye drops containing preservatives or not. Moreover, the ophthalmologists assessed ocular signs such as redness, lid swelling, lid scale or crusts, conjunctival hyperaemia, chemosis, positive corneal and conjunctival fluorescein staining on a 4-point ordinal scale from 0 (absent) to 3 (severe). In addition, the investigators were asked to answer the question: "Regarding tolerability, is the patient satisfied with his/her preservative-free latanoprost treatment?" (Very satisfied, satisfied, unsatisfied, very unsatisfied).

Figure 1 shows the questionnaire used to conduct the study. The patient's subjective experience of tolerability to PFL was defined as the primary variable. Patients reported their subjective experience of the tolerability of their previous glaucoma treatment and of their current PFL on a Visual Analogue Scale (VAS, from 0 mm [very bad tolerance] to 100 mm [very good tolerance]). Moreover, they reported their opinion concerning the tolerability of PFL compared to their previous treatment (much better tolerated, better tolerated, identically tolerated, less well tolerated or much less well tolerated) and their experience of the ease of use of current PF latanoprost compared to their previous treatment (much easier to use/easier to use/ same/less easy to use/much less easy to use).

Continuous variables were described in terms of numbers, mean, standard deviation (SD), median with minimum and maximum, as appropriate. Categorical variables

- State of the sta									
		PATIENT M	N°1			PA	TIENT FEELING ASSESSI	MENT	
	Id N	umber:	1.1			According to	the patient, how is his tolerance	to Monoprost®?	
		e of visit:   / _ / _				Ask the patient to	evaluate his/her tolerance on the visual	l analogue scale belov	<i>N</i> .
PATIENT QUESTINNAIRE			der: 🗌 Male 🗌 Female			(0 corresp	onding to a very bad tolerance, and 100 very	good tolerance)	
	Didt	thepatientreadthePatier	nt Information letter? 🗌 y	es 🗌 no		Very bad tolerance 0		100	Verygood tolerance
		OMA HISTORY				(please use the provided ruler) How w	as the tolerance of the previous	treatment?	
						Very bad tolerance 0		100	Very good tolerance
Glaucoma or ocular hypertension diagnosed on:    (year)						Measured value:   mm (please use the provided ruler)		1 200	,
TYPE OF GLAUCOMA						Regarding tolerance, is the patie	nt satisfied with Monoprost@?		
PRIMARY	Open angle (High a	h and low tension) SECONDARY Pigmentary SECONDARY SECONDARY					atisfied Unsatis	sfied	Very unsatisfied
	Congenital					In comparison with the previous			
						> REGARDING TOLERANCE IS MC			
RE:    mmHg I		P MEASUREMENT	LE:  ⊥  mmHg	LE:  ⊥  mmHg			-	Less tolerated	Much lesstolerate
RE	STAG	E OF GLAUCOMA	LE					Less tolerated	
	Ocu	lar hypertension				> REGARDING EASINESS OF USE	IS MONOPROST® CONSIDERED	AS:	
	Early	glaucoma (< 6 dB)				Much more easy to use More	easyto use 🗌 Same 🗌	Less easy to use	Much less easy to use
		e glaucoma (6-12 dB)							
	Severe	glaucoma (>12 dB)					OCULAR SURFACE DISEA		
	1					In concomitance with Monoprost		iy ocular surface o	disease?
	TO								
		FATMENTS				No No	Yes		
		EATMENTS				If yes, what is the severity?			
Start of glaucoma treatment	with Monoprost®: Ti	ick the appropriate boxes to in	dicate the previous treatment (o	only the last one	2)	If yes, what is the severity?	Moderate		Severe
Start of glaucoma treatment v	with Monoprost®:		e answers allowed)		a)	If yes, what is the severity?  Mild In addition to Monoprost®, is the	 Moderate e patient frequently using tear su	ubstitutes?	Severe
(day) /    (month) /	with Monoprost®: Ti (ir	ick the appropriate boxes to in	e answers allowed)	only the last one evious	e)	If yes, what is the severity? Mild In addition to Monoprost®, is the	Moderate e patient frequently using tear su		Severe
Image: line state of the patient take other glas	with Monoprost®: Ti (ir  (year) aucoma	ick the appropriate boxes to in n case of combination, multipl TREATMI	e answers allowed)		2)	If yes, what is the severity?  Mild  In addition to Monoprost®, is the No  If yes, since the start of Monopro	☐ Moderate e patient frequently using tear su ☐ Yes pst@, has the use of tear substitu		
(day) /    (month) /	with Monoprost®: The first of t	ick the appropriate boxes to in n case of combination, multipl TREATMI Bimateprost 0.01%	e answers allowed)	EVIOUS LE P PF	a)	If yes, what is the severity?  Mild  In addition to Monoprost®, is the No  If yes, since the start of Monopro	Moderate     patient frequently using tear su     Yes     Yes     ves     decreased	utes	No change
Did the patient take other glat treatments in the past?	with Monoprost®: Th (ir  (year) aucoma	ick the appropriate boxes to in n case of combination, multipl TREATMI Bimatoprost 0.01% Bimatoprost 0.03%	E answers allowed)	EVIOUS LE P PF	e)	If yes, what is the severity? Mild In addition to Monoprost®, is the No If yes, since the start of Monopro Increased In addition to preservative free la	Moderate e patient frequently using tear su Yes stw, has the use of tear substitut e creased atanoprost, is the patient using a	utes	No change
Did the patient take other glat treatments in the past?	with Monoprost®: Th (ir ) (year) aucoma	ick the appropriate boxes to in n case of combination, multipl TREATMI Bimateprost 0.01%	e answers allowed)	EVIOUS LE P PF	2)	If yes, what is the severity?  Mild  In addition to Monoprost®, is the No  If yes, since the start of Monopro	Moderate     patient frequently using tear su     Yes     Yes     ves     decreased	utes	No change
Image: line strength       Did the patient take other glat treatments in the past?       Image: line strength       Yes     No	with Monoprost®: Th (r aucoma treatment: T trate	Ick the appropriate boxes to in n case of combination, multiply TREATMI Bimatoprost 0.03% Latanoprost Tafluprost Taroyarost	E answers allowed)	EVIOUS LE P PF C C C C C C C C C C C C C C C C C C C	2)	If yes, what is the severity? Mild In addition to Monoprost®, is the No If yes, since the start of Monopro- Increased In addition to preservative free la No	Moderate e patient frequently using tear su Yes stw, has the use of tear substitut e creased atanoprost, is the patient using a	utes any eyedrops cont	No change
Iday) / I (month) / [     Did the patient take other glat     treatments in the past?     Yes No     Date of the first glaucoma     Iday	with Monoprost®: Th (r aucoma	ck the appropriate boxes to in n case of combination, multiple TREATMI Binateprest 0.01% Binateprest 0.03% Latensprost Taflupost Tarlupost Tarlupost	ENT PR P PR P PR C C P PR P PR C C P C P C P C P C P C P C P C	EVIOUS	2)	If yes, what is the severity? Mild In addition to Monoprost®, is the If yes, since the start of Monopre Increased In addition to preservative free is No OPHT	Moderate  a patient frequently using tear su     Yes  bat®, has the use of tear substitut     decreased  atanoprost, is the patient using a     Yes  HALMOLOGICAL EXAM	utes any eyedrops cont IINATION	No change
Iday) / I (month) / [     Did the patient take other glass treatments in the past?     Yes No     Date of the first glaucoma (     IIIII) (vear)	with Monoprost®: Tr (fr aucoma treatment: Tr nge his treatment	ck the appropriate boxes to in n case of combination, multiple TREATMI Bilmatoprost 0.01% Latenargorest Traivegres	Entransitioned)	EVIOUS	2)	If yes, what is the severity? Mild In addition to Monoprost®, is the No If yes, since the start of Monopro- Increased In addition to preservative free la No	Moderate  a patient frequently using tear su     Yes  bat®, has the use of tear substitut     decreased  atanoprost, is the patient using a     Yes  HALMOLOGICAL EXAM	utes any eyedrops cont IINATION	No change
Limit (day) / Limit (month) / L     Did the patient take other glat treatments in the past?     Yes No     Date of the first glaucoma     Limit (vær)     How many times did he chans since this first glaucoma treat	with Monoprost.®: Tr (r (r aucoma treatment: T r nge his treatment c turnent?	ck the appropriate boxes to in n case of combination, multiple TREATMI Binateprest 0.01% Binateprest 0.03% Latensprost Taflupost Tarlupost Tarlupost	ENT PR P PR P PR C C P PR P PR C C P C P C P C P C P C P C P C	EVIOUS	3)	If yes, what is the severity? Mild In addition to Monoprost®, is the No If yes, since the start of Monopro Increased In addition to preservative free la No OPHT Evaluate the ocular signs of your patient RE O	Moderate e patient frequently using tear su     Yes est®, has the use of tear substitu     decreased atanoprost, is the patient using a     Yes HALMOLOGICAL EXAM on a scale from 0 (absent) to 3 (severe) Lid redness	utes any eyedrops cont IINATION ):	No change taining preservative
Iday) / I (month) / [     Did the patient take other glass treatments in the past?     Yes No     Date of the first glaucoma (     IIIII) (vear)	with Monoprost.®: Tr (r (r aucoma treatment: T r nge his treatment c turnent?	ck the appropriate boxes to in n case of combination, multiple TREATMI Bilimatoprost 0.03% Latanoprost Latanoprost Beta-Nicoker Carbonic anhydrase inhibitor Myha 2 agonist	Entransitioned)	EVIOUS	2)	If yes, what is the severity? Mild In addition to Monoprost@, is the No If yes, since the start of Monopro Increased In addition to preservative free le No OPHT Evaluate the ocular signs of your patient RE O 1 2 3	Moderate  a patient frequently using tear su Yes  stw, has the use of tear substitu decreased atanoprost, is the patient using a Yes  HALMOLOCICAL EXAM on a scale from 0 (absert) to 3 (severe) Lid redness Lid swelling	utes any eyedrops cont INATION ):	No change taining preservative
Limit (day) / Limit (month) / L     Did the patient take other glat treatments in the past?     Yes No     Date of the first glaucoma     Limit (veer)     How many times did he chans     since this first glaucoma treat	with Monoprost.®: Tr (r (r aucoma treatment: T r nge his treatment c turnent?	ck the appropriate boxes to in n case of combination, multiple TREATMI Bilmategreat 0.01% Bilmategreat 0.03% Latenegreat Travegreat Beta-blocker Zarbenic anhydrase inhibiter Alpha 2 agenist Other glaucena treatment, specify:	Participation         Participation           ENT         Participation         Participation           Participation         Participation         Participation           Participation         Participation         Participation           Participation         Participation         Participation           Participation         Participation         Participation	EVIOUS	2)	If yes, what is the severity? Mild In addition to Monoprost(#), is the No If yes, since the start of Monopro Increased In addition to preservative free ic No OPHT Evaluate the occlar signs of your patient TE O O O O O O O O O O O O O O O O O O	Moderate e patient frequently using tear su     Yes ost.@, has the use of tear substitu     decreased atanoprost, is the patient using a     Yes HALMOLOGICAL EXAM on a scale from 0 (absent) to 3 (severe)     Lid redenss     Lid scale or crusts     Lid scale or crusts	INATION	No change taining preservative LE 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3
Limit (day) / Limit (month) / L     Did the patient take other glat treatments in the past?     Yes No     Date of the first glaucoma     Limit (vær)     How many times did he chans since this first glaucoma treat	with Monoprost.®: Tr (r (r aucoma treatment: T r nge his treatment c turnent?	ck the appropriate boxes to in n case of combination, multiple TREATMI Bilimatoprost 0.03% Latanoprost Latanoprost Beta-Nicoker Carbonic anhydrase inhibitor Myha 2 agonist	Participation         Participation           ENT         Participation         Participation           Participation         Participation         Participation           Participation         Participation         Participation           Participation         Participation         Participation           Participation         Participation         Participation	EVIOUS	3)	If yes, what is the severity? Mild In addition to Monoprost(b), is the No If yes, since the start of Monopro Increased In addition to preservative free la No OPHT Evaluate the ocular signs of your patient CC	Moderate e patient frequently using tear su     Yes ests®, has the use of tear substitu     decreased atanoprost, is the patient using a     Yes HALMOLOGICAL EXAM on a scale from 0 (absent) to 3 (severe;     Lid swelling,     Lid sale or crusts	INATION	No change taining preservativ 1 2 3 1 2 2 3
Limit (day) / Limit (month) / L     Did the patient take other glat treatments in the past?     Yes No     Date of the first glaucoma     Limit (vær)     How many times did he chans since this first glaucoma treat	with Monoprosta: Tr (re aucoma treatment: rge his treatment trment?	ck the appropriate boxes to in n case of combination, multiple Interaction of the second of the second Interaction of the second of the second Interaction of the second of the second of the second Interaction of the second of the secon	e answers allowed)  ENT  ENT	EVIOUS	3)	If yes, what is the severity? Mild In addition to Monoprost(8), is the No If yes, since the start of Monopro Increased In addition to preservative free la No CPHT Evaluate the coular signs of your patient IC 2 3 O 1 2 2 3 O 1 2 2 3 O 1 2 2 3 O 1 2 2 3 O 1 2 2 3 O 1 2 2 3 O 1 2 2	Moderate e patient frequently using tear su     Yes estew, has the use of tear substitu     decreased atanoprost, is the patient using a     Yes HALMOLOGICAL EXAM on a scale from 0 (absent) to 3 (severe)     det areaters     det areaters     det areaters     det areaters     Genousis     Fluorconneal     Fluor congulational	INATION	No change taining preservativ
Iday) / I (month) / [     Did the patient take other glas     treatments in the past?     Yes No     Date of the first glaucoma     ILLLI (vear)     How many times did he chang     since this first glaucoma treat     LLI (times)	with Monoprosta: Tr (re aucoma treatment: rge his treatment trment?	ck the appropriate boxes to in n case of combination, multiple <b>TREATMI</b> Bilmatoprost 0.0.1% Establishment Travoprost Beta-Biological Carbonic analysisse inhibitor Alpha 2 sponist Other glaxcoma treatment, specify: Beta-Rijke Syr; Let (eff Syr; P > Pro- t, what was the reasolo	e answers allowed)  ENT  ENT	EVIOUS	2)	If yes, what is the severity? Mild In addition to Monoprost(8), is the No If yes, since the start of Monopro Increased In addition to preservative free is No OPHT Evaluate the ocular signs of your patient IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII	Moderate e patient frequently using tear su     Ves st     to tear substitut     decreased atanoprost, is the patient using a     Ves HALMOLOCICAL EXAM on a scale from 0 (absent) to 3 (severe)     Lid redness     Lid redness     Lid redness     Furenosis     Furenosis     Furenosis	INATION INATION ): 00 00 00 00 00 00 00 00 00 0	No change taining preservativ

Figure I Questionnaire used during the study.

were given as absolute frequency and percentage per category. Confidence intervals at 95% were given where applicable. A logistic regression analysis was used to identify parameters associated with patients' satisfaction with their current PFL treatment. Odds ratios and p-values were determined, as appropriate. An ad-hoc analysis was performed on treatment-naïve patients who had received no previous treatment prior to their current PFL.

### Results

# Patient Disposition, Demographics and Disease Characteristics

A total of 1872 patients were recruited (Spain, 1303; Germany, 213; Portugal, 168; Belgium 104; Switzerland 59; Netherlands, 25). Age was 66.8±12.11 years; mainly women participated (60.9%). Patients had mostly early glaucoma (41.5%) or ocular hypertension (29.9%); (Table 1).

In total, 76.2% had been treated for their glaucoma prior to their current PFL use; 69.4% had received

a preservative-containing treatment and 6.8% had received PF eye drops.

On average, patients who were previously treated switched treatment  $2.4 \pm 1.86$  times; although some had experienced up to 20 treatment switches. The most common reason for switching to PFL was local intolerance (61.8%), followed by insufficient efficacy (49.1%). Insufficient compliance, systemic intolerance, patient request and other reasons were cited by fewer than 10%.

The mean exposure to PFL was  $149.5 \pm 83.9$  days; mean IOP was  $18.4 \pm 4.87$  mmHg (n=3744 eyes).

### Patient Satisfaction

Overall, 95.3% of the patients were satisfied (55.2%) or very satisfied (40.1%) with PFL regarding tolerability. Only 3.5% were unsatisfied and 0.7% very unsatisfied; data were missing for 0.5%. The proportion of patients satisfied with PFL was similar among patients who had previously received preserved medication (95%) and among those who were treatment-naive (97.3%).

1872			
66.8 ± 12.11			
[18–99]			
1872			
60.9%			
38.6%			
0.5%			
17.6 ± 4.30			
1872			
85.7%			
12.1%			
2.2%			
3744 eyes			
29.9%			
41.5%			
16.7%			
8.3%			

Table I Demographic and Baseline Disease Characteristics

Patients were significantly (p<0.0001) more satisfied with the tolerability to PFL (VAS score  $83.5 \pm 16.5$ ), than with that of their previous treatment (VAS score  $57.7 \pm 27.2$ ). Among patients who had previously received a preservativecontaining topical glaucoma therapy, tolerability scores on the VAS increased from  $56.6 \pm 27.2$  to  $82.6 \pm 16.8$ , corresponding to an improvement of 45.9%. For treatment-naive patients, the mean tolerance to PFL, evaluated with VAS, was even higher ( $86.7 \pm 13.9$ ); refer to Figure 2 for details. According to the different types of previous preserved treatments, improvement of tolerability differed.

After having switched to PFL from the most current treatments, the individual improvement of VAS score was 82% from bimatoprost 0.3%, 70% from bimatoprost 0.1%, 63% from travoprost, 42% from preserved latanoprost, 35% from tafluprost and 38% frombeta-blockers.

### Tolerability Compared to Previous Treatment

The proportion of patients who provided a positive assessment of tolerance to PFL was 75.2%, with 58.7% of patients in the preserved and preservative-free subgroups. The proportion of patients who reported tolerance to PFL to be better, much better or the same as their previous treatment was therefore 95.8% for the preserved sub-group and 93.6% for the preservative-free sub-group. A lower proportion of patients in the preserved and preservative-free sub-groups considered tolerance to PFL to be less (2.7% and 4.8%, respectively) and much less (0.5% and 1.6%, respectively) than their previous treatments.

### Ease of Use

In total, 48.8% of patients rated PFL to be as easy to use as their previous treatment in drop bottles, 29.4% rated it easier and 11.3% much easier to use. Only 9.3% of patients considered it to be less easy to use; for 1.2%, data were missing.

### Ocular Surface Disease

OSD was diagnosed in 9.2% of patients (n=173) and was mainly mild (76.9%). Lid redness was the most




Figure 2 Mean tolerability assessed with Visual Analogue Scale in patients receiving PF latanoprost (n=1817). p<0.01. Abbreviations: PFL, preservative-free latanoprost; naïve, previously untreated patients. common ocular sign among patients with OSD. Lid redness, lid swelling, lid scale or crusts and chemosis showed no statistically significant difference between patients with preserved therapy and patients with PFL (Figure 3).

# TBUT, Conjunctival Hyperaemia and Fluorescein Staining

TBUT was performed for 1649 eyes. It was inferior to 5 seconds for 10.8% and inferior to 10 seconds for 52.3% of the eyes.

Even though the fluorescein staining of the cornea and conjunctiva as well as the conjunctival hyperaemia showed no statistical difference between the individual therapy groups, the ocular status was slightly better in treatment naïve patients compared to that of patients who had previously been treated (Figures 4 and 5).

### Use of Tear Substitutes

Overall, 45.4% of patients used tear substitutes concomitantly. This use decreased for 24.1% of these patients after they had switched to PFL. Among patients who had previously received a preserved therapy, 28.1% reported reduced tear substitute use following the switch to PFL. A total of 30% of treatment-naïve patients used tear substitutes concomitantly with PFL.

# Association of Study Parameters with Patient Satisfaction

Patient satisfaction with PFL was significantly associated with improved tolerance after use (p<0.0001), tolerability regarding the current medication (p<0.0001), ease-of-use (p<0.0001), reduction of tear substitute use after having switched to PFL (p<0.0001), absence of ocular symptoms (p<0.0004), absence of OSD (p<0.0001), use of prior treatment (p<0.05) and use of tear substitutes (p<0.02).

### Discussion

Glaucoma treatment is life-long and, as with all long-term prophylactic treatments, compliance is a major issue.<sup>3,8</sup> Preservatives in topical glaucoma medication have well-described toxic effects which trigger OSD and impact treatment compliance.<sup>5,8,21–23</sup> A study showed that OSD are common among glaucoma patients receiving topical therapy and that it is both more common and more severe






Figure 3 Ocular signs under previous treatment, preservative-free latanoprost treatment and in naïve patients. Abbreviations: P, previous treatment; PFL, preservative-free latanoprost; naïve, previously untreated patients.



■missing data ■severe ■moderate ■mild ■absent






Figure 5 Conjunctival hyperaemia under previous treatment, preservative-free latanoprost treatment and in naïve patients. Abbreviations: P, previous treatment; PFL, preservative-free latanoprost; naïve, untreated patients.

in older patients and in those receiving multiple treatments. Moreover, the severity of OSD has been associated with low effective control of IOP.<sup>24</sup>

The majority of patients who entered the present study had switched several times from preserved monotherapy. However, the relatively high number of included treatmentnaive patients allowed for an ad-hoc subgroup analysis.

Surprisingly, 6.8% of patients who switched to PFL, previously used preservative-free drops. This change may be due to tolerability issues as reported by Duru et al for preservative-free brimonidine tartrate.<sup>25</sup> However, study results are based on a very small sample size and a comparative study may help to shade some light on the observed phenomenon. Regarding tolerability, patients were more satisfied with PFL than with their previous preserved treatment (45.9% improvement on average on the VAS); 75.2% of patients considered the tolerability of PFL as better or much better than their previous preserved treatment, although it was changed from drop bottles to PFL.

Overall, 42% assessed the PFL as easier or much easier to use than their previous treatment. Furthermore, the use of PFL led to a lower percentage of patients using tear substitutes in the subgroup of treatment-naïve patients, and a decreased use in a quarter of patients after switching from a previous treatment. Artificial tears are currently used to treat dry eye, known to be caused by preservatives

such as benzalkonium chloride.<sup>26</sup> Eliminating preservatives in glaucoma treatments may, therefore, reduce the use of artificial tears.

Not surprisingly, the most common reason for switching to PFL was local intolerance, a well-known issue in the context of the local toxicity of preserved treatments previously used by a large majority of the included patients. The second most common reason was insufficient efficacy, which could be potentially explained by poor treatment adherence, due to local tolerability issues.

More than 97% of treatment-naïve patients were satisfied with PFL. OSD was reported in less than 7% of patients and, when it occurred, severity was generally mild. Conjunctival hyperaemia is a recognized adverse event of topical prostaglandin analogues, although it appears to be a less frequent problem with latanoprost than with other prostaglandin analogues, and its incidence remained relatively high after the switch (58.7%).<sup>27,28</sup> The incidence of conjunctival hyperaemia was relatively low among patients in this study and was rarely severe.

Despite these encouraging results, the study has several limitations and bias:1. This was not a comparative, randomised study making a direct comparison between preserved drops and PFL impossible.2. The low number of patients in the subgroups previously treated by PF glaucoma treatment (126 patients), representing only 6.8% of the overall study population compared to other sub-groups requires further investigations in order to support the benefits of PFL in glaucoma for all different patient profiles. Additional randomised studies comparing the prevalence in the preserved and PF groups or switching treatments are needed, in order to provide unequivocal evidence of an improvement of signs/symptoms and the long-term benefit of PF treatments.3. Investigators asked their patients to estimate their treatment satisfaction without asking for the reason for dissatisfaction. This may cause a bias, which may potentially lead to an overestimation of patient satisfaction, as patients might not have wanted to contradict their ophthalmologist and, thereby, tended to minimize potential symptoms, which limits the understanding of the reasons for dissatisfaction.4. A logistic regression was used to determine whether patient satisfaction was related to other variables. Each variable was analysed in a separate logistic regression model as a predictor for being satisfied with PFL. With satisfaction potentially being multifactorial, the analysis was not performed with multiple comparison methods or used for adjusting the overall  $\alpha$ -level. The poor tolerability of glaucoma

Erb et al

medication may lead to poor treatment compliance and, therefore, to treatment failure. Patients' evaluation of their tolerance to glaucoma treatment is key to assessing treatment efficacy. Moreover, the usability of the dropper device is worthy of consideration; a study suggests that the force required to expel a drop from some devices is beyond the physical capability of many patients.<sup>28</sup>

The study shows that preservative-free latanoprost may be a valuable choice of therapy when switching patients from preserved treatment due to tolerability issues, and may be considered as first choice in newly diagnosed glaucoma patients.<sup>29</sup>

In conclusion, after at least 3 months of treatment with PF latanoprost, patient satisfaction was very high and potentially led to a reduced use of tear substitutes.

### Acknowledgments

The authors acknowledge the participation of the PASSY study team and of their patients and the writing assistance of Karl Patrick Göritz, SMWS, France.

### Funding

The study was funded by Laboratoires Théa, Clermont-Ferrand, France.

### Disclosure

Prof. Carl Erb received consultancies from Aerie, Alcon, Allergan, Bayer. Bausch&Lomb, Thea. Santen, OmniVision, Ophtaprotect, Oculus, Glaukos and Zeiss. Prof. Ingeborg Stalmans received consultancies and research grants from Aerie, Alcon, Allergan, EyeD Pharma, EyeTechCare, Horus Pharma, Oculis, Santen, Laboratoires Théa, and Zeiss. Prof. Milko Iliev received consultancies and research grants from Thea, Santen, and Allergan. Prof. Francisco José Muñoz-Negrete received consultancies and research grants from Alcon, Avizor, Bayer, Esteve, Laboratoires Théa, and Santen. The authors report no other conflicts of interest in this work.

### References

- 1. Vélez-Gómez MC, Vásquez-Trespalacios EM. Adherence to topical treatment of glaucoma, risk and protective factors: a review. Arch Soc Esp Oftalmol. 2018;93(2):87-92. doi:10.1016/j.oftal.2017.07.012
- 2. Molina-Castañer S. Terminology and guidelines for glaucoma. Arch Soc Esp Oftalmol. 2009;84(10):543-544.
- 3. Lemij HG, Hoevenaars JG, van der Windt C, Baudouin C. Patient satisfaction with glaucoma therapy: reality or myth? Clin Ophthalmol. 2015;9:785-793. doi:10.2147/OPTH.S78918

- Yeaw J, Benner JS, Walt JG, Sian S, Smith DB. Comparing adherence and persistence across 6 chronic medication classes. *J Manag Care Pharm.* 2009;15(9):728–740. doi:10.18553/jmcp.2009.15.9.728
- Baudouin C, Liang H, Hamard P, et al. The ocular surface of glaucoma patients treated over the long term expresses inflammatory markers related to both T-helper 1 and T-helper 2 pathways. *Ophthalmology*. 2008;115(1):109–115. doi:10.1016/j.ophtha.2007.01.036
- Kestelyn PA, Kestelyn PG, De Bacquer D, Stevens AM. Switch from BAK-preserved to preservative-free latanoprost decreases anterior chamber flare in POAG patients. *Int Ophthalmol.* 2019;39 (1):105–109. doi:10.1007/s10792-017-0792-z
- Inoue D, Mohamed YH, Uematsu M, Kitaoka T. Corneal damage and its recovery after instillation of preservative-free versus preserved latanoprost eye drops. *Cutan Ocul Toxicol.* 2020;39(2):158–164. doi:10.1080/15569527.2020.1752228
- Baudouin C, Labbe A, Liang H, Pauly A, Brignole-Baudouin F. Preservatives in eyedrops: the good, the bad and the ugly. *Prog Retin Eye Res.* 2010;29(4):312–334. doi:10.1016/j.preteyeres.2010.03.001
- European glaucoma society terminology and guidelines for glaucoma, 4th edition - chapter 3: treatment principles and options supported by the EGS foundation: part 1: foreword; introduction; glossary; chapter 3 treatment principles and options. Br J Ophthalmol. 2017;101(6):130–195.
- Alm A. Latanoprost in the treatment of glaucoma. *Clin Ophthalmol.* 2014;8:1967–1985. doi:10.2147/OPTH.S59162
- Arias A, Schargel K, Ussa F, Canut MI, Robles AY, Sanchez BM. Patient persistence with first-line antiglaucomatous monotherapy. *Clin Ophthalmol.* 2010;4:261–267. doi:10.2147/opth.s7971
- Rouland JF, Traverso CE, Stalmans I, et al. Efficacy and safety of preservative-free latanoprost eyedrops, compared with BAK-preserved latanoprost in patients with ocular hypertension or glaucoma. *Br J Ophthalmol.* 2013;97(2):196–200. doi:10.1136/ bjophthalmol-2012-302121
- Heo JH, Rascati KL, Wilson JP, Lawson KA, Richards KM, Nair R. Comparison of prostaglandin analog treatment patterns in glaucoma and ocular hypertension. *J Manag Care Spec Pharm.* 2019;25 (9):1001–1010. doi:10.18553/jmcp.2019.25.9.1001
- 14. Cucherat M, Stalmans I, Rouland JF. Relative efficacy and safety of preservative-free latanoprost (T2345) for the treatment of open-angle glaucoma and ocular hypertension: an adjusted indirect comparison meta-analysis of randomized clinical trials. *J Glaucoma*. 2014;23(1): e69–e75. doi:10.1097/IJG.0b013e3182a075e6
- Pisella PJ, Pouliquen P, Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. *Br J Ophthalmol.* 2002;86(4):418–423. doi:10.1136/bjo.86.4.418
- 16. Jaenen N, Baudouin C, Pouliquen P, Manni G, Figueiredo A, Zeyen T. Ocular symptoms and signs with preserved and preservative-free glaucoma medications. *Eur J Ophthalmol.* 2007;17 (3):341–349. doi:10.1177/112067210701700311
- Thygesen J. Glaucoma therapy: preservative-free for all? Clin Ophthalmol. 2018;12:707–717. doi:10.2147/OPTH.S150816

- Misiuk-Hojlo M, Pomorska M, Mulak M, et al. The RELIEF study: tolerability and efficacy of preservative-free latanoprost in the treatment of glaucoma or ocular hypertension. *Eur J Ophthalmol.* 2019;29 (2):210–215. doi:10.1177/1120672118785280
- Munoz Negrete FJ, Lemij HG, Erb C. Switching to preservative-free latanoprost: impact on tolerability and patient satisfaction. *Clin Ophthalmol.* 2017;11:557–566. doi:10.2147/OPTH.S126042
- IEA. International Epidemiological Association: Good Epidemiological Practice (GEP), IEA guidelines for proper conduct in epidemiological research. November, 2007 Available from: http:// ieaweb.org/good-epidemiological-practice-gep/. Accessed November 8, 2020.
- Hakkarainen JJ, Reinisalo M, Ragauskas S, Seppänen A, Kaja S, Kalesnykas G. Acute cytotoxic effects of marketed ophthalmic formulations on human corneal epithelial cells. *Int J Pharm.* 2016;511 (1):73–78. doi:10.1016/j.ijpharm.2016.06.135
- Pérez-Bartolomé F, Martínez-de-la-casa JM, Arriola-Villalobos P, Fernández-Pérez C, Polo V, García-Feijoó J. Ocular surface disease in patients under topical treatment for glaucoma. *Eur J Ophthalmol.* 2017;27(6):694–704. doi:10.5301/ejo.5000977
- Martinez-de-la-casa JM, Perez-Bartolome F, Urcelay E, et al. Tear cytokine profile of glaucoma patients treated with preservative-free or preserved latanoprost. *Ocul Surf*. 2017;15(4):723–729. doi:10.1016/j. jtos.2017.03.004
- 24. Baudouin C, Renard JP, Nordmann JP, et al. Prevalence and risk factors for ocular surface disease among patients treated over the long term for glaucoma or ocular hypertension. *Eur J Ophthalmol.* 2013;23(1):47–54. doi:10.5301/ejo.5000181
- 25. Duru Z, Ozsaygili C. Preservative-free versus preserved brimonidine %0.15 preparations in the treatment of glaucoma and ocular hypertension: short term evaluation of efficacy, safety, and potential advantages. *Cutan Ocul Toxicol*. 2020;39(1):21–24. doi:10.1080/15 569527.2019.1680685
- Walsh K, Jones L. The use of preservatives in dry eye drops. *Clin Ophthalmol.* 2019;13:1409–1425. doi:10.2147/OPTH.S211611
- Feldman RM. Conjunctival hyperemia and the use of topical prostaglandins in glaucoma and ocular hypertension. J Ocul Pharmacol Ther. 2003;19(1):23–35. doi:10.1089/108076803762718088
- Honrubia F, Garcia-Sanchez J, Polo V, de la Casa JM, Soto J. Conjunctival hyperaemia with the use of latanoprost versus other prostaglandin analogues in patients with ocular hypertension or glaucoma: a meta-analysis of randomised clinical trials. *Br J Ophthalmol.* 2009;93(3):316–321. doi:10.1136/bjo.2007.135111
- Economou MA, Laukeland HK, Grabska-Liberek I, Rouland JF. Better tolerance of preservative-free latanoprost compared to preserved glaucoma eye drops: the 12-month real-life FREE study. *Clin Ophthalmol.* 2018;12:2399–2407. doi:10.2147/ OPTH.S176605

#### Clinical Ophthalmology

#### Publish your work in this journal

Clinical Ophthalmology is an international, peer-reviewed journal covering all subspecialties within ophthalmology. Key topics include: Optometry; Visual science; Pharmacology and drug therapy in eye diseases; Basic Sciences; Primary and Secondary eye care; Patient Safety and Quality of Care Improvements. This journal is indexed on PubMed

Submit your manuscript here: https://www.dovepress.com/clinical-ophthalmology-journal

### **Dove**press

Central and CAS, and is the official journal of The Society of Clinical Ophthalmology (SCO). The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.